REFERENCES
1. Ungvari Z, Kaley G, de Cabo R, Sonntag WE, Csiszar A. Mechanisms of vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci 2010;65:1028-41.
2. Peiyong Z, Junichi S. Cardiomyocyte senescence and the potential therapeutic role of senolytics in the heart. J Cardiovasc Aging 2024;4:18.
3. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell 2023;186:243-78.
4. Bergmann O, Zdunek S, Felker A, et al. Dynamics of cell generation and turnover in the human heart. Cell 2015;161:1566-75.
5. Ozcebe SG, Zorlutuna P. In need of age-appropriate cardiac models: impact of cell age on extracellular matrix therapy outcomes. Aging Cell 2023;22:e13966.
6. Feng J, Li Y, Li Y, et al. Versican promotes cardiomyocyte proliferation and cardiac repair. Circulation 2024;149:1004-15.
7. Budhathoki S, Graham C, Sethu P, Kannappan R. Engineered aging cardiac tissue chip model for studying cardiovascular disease. Cells Tissues Organs 2022;211:348-59.
8. Acun A, Nguyen TD, Zorlutuna P. In vitro aged, hiPSC-origin engineered heart tissue models with age-dependent functional deterioration to study myocardial infarction. Acta Biomater 2019;94:372-91.
9. Anderson R, Lagnado A, Maggiorani D, et al. Length-independent telomere damage drives post-mitotic cardiomyocyte senescence. EMBO J 2019;38:e100492.
10. Ye Y, Yang K, Liu H, et al. SIRT2 counteracts primate cardiac aging via deacetylation of STAT3 that silences CDKN2B. Nat Aging 2023;3:1269-87.
11. Mone P, Agyapong ED, Morciano G, et al. Dysfunctional mitochondria elicit bioenergetic decline in the aged heart. J Cardiovasc Aging 4 2024:13.
12. Abutaleb NO, Atchison L, Choi L, et al. Lonafarnib and everolimus reduce pathology in iPSC-derived tissue engineered blood vessel model of Hutchinson-Gilford Progeria Syndrome. Sci Rep 2023;13:5032.
13. Atchison L, Zhang H, Cao K, Truskey GA. A tissue engineered blood vessel model of hutchinson-gilford progeria syndrome using human iPSC-derived smooth muscle cells. Sci Rep 2017;7:8168.
14. Atchison L, Abutaleb NO, Snyder-Mounts E, et al. iPSC-derived endothelial cells affect vascular function in a tissue-engineered blood vessel model of hutchinson-gilford progeria syndrome. Stem Cell Reports 2020;14:325-37.
15. Miller JD, Ganat YM, Kishinevsky S, et al. Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell 2013;13:691-705.
16. Dechat T, Pfleghaar K, Sengupta K, et al. Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Genes Dev 2008;22:832-53.
17. Dogacan Y, William TP. From vitality to vulnerability: the impact of oxygen on cardiac function and regeneration. J Cardiovasc Aging 2024;4:15.
18. Ungvari Z, Tarantini S, Kiss T, et al. Endothelial dysfunction and angiogenesis impairment in the ageing vasculature. Nat Rev Cardiol 2018;15:555-65.
19. Salmon EE, Breithaupt JJ, Truskey GA. Application of oxidative stress to a tissue-engineered vascular aging model induces endothelial cell senescence and activation. Cells 2020;9:1292.
20. Spallarossa P, Altieri P, Aloi C, et al. Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2. Am J Physiol Heart Circ Physiol 2009;297:H2169-81.
21. Maejima Y, Adachi S, Ito H, Hirao K, Isobe M. Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage. Aging Cell 2008;7:125-36.
22. Liu C, Zhang X, Hu M, et al. Metabolic targets in cardiac aging and rejuvenation. J Cardiovasc Aging 2022;2:46.
23. Bassat E, Tzahor E. How can young extracellular matrix promote cardiac regeneration? Circulation 2024;149:1016-8.
24. Tzahor E, Dimmeler S. A coalition to heal-the impact of the cardiac microenvironment. Science 2022;377:eabm4443.
25. Sun S, Qin W, Tang X, et al. Vascular endothelium-targeted Sirt7 gene therapy rejuvenates blood vessels and extends life span in a Hutchinson-Gilford progeria model. Sci Adv 2020;6:eaay5556.
26. Zhuang L, Jia K, Chen C, et al. DYRK1B-STAT3 Drives cardiac hypertrophy and heart failure by impairing mitochondrial bioenergetics. Circulation 2022;145:829-46.
27. Bui L, Edwards S, Hall E, et al. Engineering bioactive nanoparticles to rejuvenate vascular progenitor cells. Commun Biol 2022;5:635.
28. Zhang N, Zhu J, Ma Q, et al. Exosomes derived from human umbilical cord MSCs rejuvenate aged MSCs and enhance their functions for myocardial repair. Stem Cell Res Ther 2020;11:273.
29. Grigorian-Shamagian L, Liu W, Fereydooni S, et al. Cardiac and systemic rejuvenation after cardiosphere-derived cell therapy in senescent rats. Eur Heart J 2017;38:2957-67.
30. Kang K, Sun L, Xiao Y, et al. Aged human cells rejuvenated by cytokine enhancement of biomaterials for surgical ventricular restoration. J Am Coll Cardiol 2012;60:2237-49.
31. Omori S, Wang TW, Johmura Y, et al. Generation of a p16 reporter mouse and its use to characterize and target p16(high) cells in vivo. Cell Metab 2020;32:814-28.
32. Wang B, Wang L, Gasek NS, et al. An inducible p21-Cre mouse model to monitor and manipulate p21-highly-expressing senescent cells in vivo. Nat Aging 2021;1:962-73.
33. Amor C, Feucht J, Leibold J, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 2020;583:127-32.
34. Suda M, Shimizu I, Katsuumi G, et al. Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. Nat Aging 2021;1:1117-26.
35. Baker DJ, Wijshake T, Tchkonia T, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 2011;479:232-6.
36. Farr JN, Saul D, Doolittle ML, et al. Local senolysis in aged mice only partially replicates the benefits of systemic senolysis. J Clin Invest 2023;133:e162519.
37. Demaria M, Ohtani N, Youssef SA, et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell 2014;31:722-33.
38. Ward MR, Abadeh A, Connelly KA. Concise review: rational use of mesenchymal stem cells in the treatment of ischemic heart disease. Stem Cells Transl Med 2018;7:543-50.
39. Zhang K, Cheng K. Stem cell-derived exosome versus stem cell therapy. Nat Rev Bioeng 2023;12:1-2.
40. Zhang H, Xue Y, Pan T, et al. Epicardial injection of allogeneic human-induced-pluripotent stem cell-derived cardiomyocytes in patients with advanced heart failure: protocol for a phase I/IIa dose-escalation clinical trial. BMJ Open 2022;12:e056264.
41. Gerbin KA, Yang X, Murry CE, Coulombe KL. Enhanced electrical integration of engineered human myocardium via intramyocardial versus epicardial delivery in infarcted rat hearts. PLoS One 2015;10:e0131446.
42. Zhao X, Chen H, Xiao D, et al. Comparison of non-human primate versus human induced pluripotent stem cell-derived cardiomyocytes for treatment of myocardial infarction. Stem Cell Reports 2018;10:422-35.
43. Shiba Y, Fernandes S, Zhu WZ, et al. Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature 2012;489:322-5.
44. Romagnuolo R, Masoudpour H, Porta-Sánchez A, et al. Human embryonic stem cell-derived cardiomyocytes regenerate the infarcted pig heart but induce ventricular tachyarrhythmias. Stem Cell Reports 2019;12:967-81.
45. Chong JJ, Yang X, Don CW, et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 2014;510:273-7.
46. Liu YW, Chen B, Yang X, et al. Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates. Nat Biotechnol 2018;36:597-605.
47. Nguyen PK, Neofytou E, Rhee JW, Wu JC. Potential strategies to address the major clinical barriers facing stem cell regenerative therapy for cardiovascular disease: a review. JAMA Cardiol 2016;1:953-62.
48. Sekine H, Shimizu T, Dobashi I, et al. Cardiac cell sheet transplantation improves damaged heart function via superior cell survival in comparison with dissociated cell injection. Tissue Eng Part A 2011;17:2973-80.
49. Riegler J, Tiburcy M, Ebert A, et al. Human engineered heart muscles engraft and survive long term in a rodent myocardial infarction model. Circ Res 2015;117:720-30.
50. Zimmermann WH, Melnychenko I, Wasmeier G, et al. Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med 2006;12:452-8.
51. Weinberger F, Breckwoldt K, Pecha S, et al. Cardiac repair in guinea pigs with human engineered heart tissue from induced pluripotent stem cells. Sci Transl Med 2016;8:363ra148.
52. Didié M, Christalla P, Rubart M, et al. Parthenogenetic stem cells for tissue-engineered heart repair. J Clin Invest 2013;123:1285-98.
53. Rubart M, Pasumarthi KB, Nakajima H, Soonpaa MH, Nakajima HO, Field LJ. Physiological coupling of donor and host cardiomyocytes after cellular transplantation. Circ Res 2003;92:1217-24.
54. Iseoka H, Miyagawa S, Fukushima S, et al. Pivotal role of non-cardiomyocytes in electromechanical and therapeutic potential of induced pluripotent stem cell-derived engineered cardiac tissue. Tissue Eng Part A 2018;24:287-300.
55. Li J, Minami I, Shiozaki M, et al. Human pluripotent stem cell-derived cardiac tissue-like constructs for repairing the infarcted myocardium. Stem Cell Reports 2017;9:1546-59.
56. Jackman CP, Ganapathi AM, Asfour H, et al. Engineered cardiac tissue patch maintains structural and electrical properties after epicardial implantation. Biomaterials 2018;159:48-58.
57. Chachques JC, Trainini JC, Lago N, et al. Myocardial assistance by grafting a new bioartificial upgraded myocardium (MAGNUM clinical trial): one year follow-up. Cell Transplant 2007;16:927-34.
58. Menasché P, Vanneaux V, Hagège A, et al. Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction. J Am Coll Cardiol 2018;71:429-38.
59. Cyranoski D. 'Reprogrammed' stem cells approved to mend human hearts for the first time. Nature 2018;557:619-20.
60. Fioretta ES, von Boehmer L, Motta SE, Lintas V, Hoerstrup SP, Emmert MY. Cardiovascular tissue engineering: from basic science to clinical application. Exp Gerontol 2019;117:1-12.
61. Kelm JM, Emmert MY, Zürcher A, et al. Functionality, growth and accelerated aging of tissue engineered living autologous vascular grafts. Biomaterials 2012;33:8277-85.
62. Zimmermann W. Tissue engineered heart repair from preclinical models to first-in-patient studies. Current Opinion in Physiology 2020;14:70-7.
63. Li Y, Asfour H, Bursac N. Age-dependent functional crosstalk between cardiac fibroblasts and cardiomyocytes in a 3D engineered cardiac tissue. Acta Biomater 2017;55:120-30.
64. Domae K, Miyagawa S, Yoshikawa Y, et al. Clinical outcomes of autologous stem cell-patch implantation for patients with heart failure with nonischemic dilated cardiomyopathy. J Am Heart Assoc 2021;10:e008649.
